InDex Pharma is on a mission to significantly improve the lives of patients suffering from immunological disorders by providing effective and safe drugs. The current focus is ulcerative colitis, a chronic and debilitating inflammation of the large intestine that affects patients of all ages, for which they have developed the candidate drug Cobitolimod.